title: Effect of secondary hyperparathyroidism treatment with cinacalcet on selected adipokines and markers of endothelial injury in hemodialysis patients: a preliminary report.
abstract: BACKGROUND
  Disturbances in endothelial function, adipokines, and mineral metabolism due to secondary hyperparathyroidism (SHPT) shorten the lifespan in hemodialysis (HD) patients.
  
  
  OBJECTIVE
  The aim of the study was to evaluate the effect of SHPT treatment with cinacalcet on selected adipokines and markers of endothelial injury in HD patients.
  
  
  METHODS
  Soluble thrombomodulin (sTM), E-selectin, leptin, and adiponectin levels were measured in patients with SHPT at baseline and at 6 months of cinacalcet treatment.
  
  
  RESULTS
  A total of 18 patients completed the study. SHPT treatment with cinacalcet decreased calcium, phosphate, and intact parathormone (iPTH) levels; however, no significant changes in sTM, E-selectin, leptin, or adiponectin were observed. iPTH levels after treatment correlated with age (r = -0.51, P =   0.031), mean cinacalcet dose (r = 0.65, P = 0.004), as well as baseline calcium (r = 0.65 P = 0.003), iPTH (r = 0.59, P = 0.01), E-selectin (r = 0.56, P = 0.016), and leptin (r = -0.49, P = 0.039).
  
  
  CONCLUSIONS
  Cinacalcet treatment does not affect the markers of endothelial function and selected adipokines. Effectiveness of treatment may be modulated by E-selectin and leptin.
authors.affiliation: Department of Nephrology and Transplantation with Dialysis Unit, Medical University of Bialystok, Białystok, Poland. tomhry@mp.pl
authors.forename: Tomasz
authors.initials: T
authors.lastname: Hryszko
authors.forename: Szymon
authors.initials: S
authors.lastname: Brzosko
authors.forename: Alicja
authors.initials: A
authors.lastname: Rydzewska-Rosołowska
authors.forename: Ewa
authors.initials: E
authors.lastname: Koc-Żórawska
authors.forename: Beata
authors.initials: B
authors.lastname: Naumnik
authors.forename: Michał
authors.initials: M
authors.lastname: Myśliwiec
mesh_terms: D054392:Adipokines / Q000097:blood*; D000368:Aged; D015415:Biomarkers / Q000097:blood; D057966:Calcimimetic Agents / Q000627:therapeutic use; D000069449:Cinacalcet; D019040:E-Selectin / Q000378:metabolism; D004730:Endothelium, Vascular / Q000378:metabolism; D005260:Female; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000097:blood* / Q000188:drug therapy*; D020738:Leptin / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000627:therapeutic use*; D006435:Renal Dialysis; D016896:Treatment Outcome
chemical_list: D054392:Adipokines; D015415:Biomarkers; D057966:Calcimimetic Agents; D019040:E-Selectin; D020738:Leptin; D009281:Naphthalenes; D000069449:Cinacalcet